bioAffinity Technologies宣布旗舰肺癌诊断产品Cypath® Lung在2025年创下营收与销量新纪录

美股速递
Yesterday

bioAffinity Technologies公司今日公布,其旗舰产品——肺癌诊断方案Cypath® Lung在2025年实现了创纪录的营收表现与单位销量。这一里程碑标志着该诊断工具在市场上的强劲增长和广泛认可。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10